Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RT003
- Development stage
- Preclinical
- Lead developer
- Revio Therapeutics
- Modality
- Small Molecules
- Administration
- Inhalation
01
Overview
RT003 is a preclinical-stage therapeutic candidate being developed by Revio Therapeutics for the treatment of respiratory and pulmonary diseases. The program involves the repurposing of an existing, approved drug into a soft mist inhalation (SMI) formulation. This delivery method is intended to optimize the delivery of the active pharmaceutical ingredient to the lungs, potentially enhancing therapeutic efficacy and patient adherence compared to conventional delivery systems. As of early 2024, the program is in the prototype proof-of-concept stage, and the specific identity of the repurposed drug and its biological target have not been publicly disclosed.
Beyond the preview
Go deeper on RT003.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RT003.